

Target	
<b>Mechanism of Action</b>	<ul style="list-style-type: none"> <li>Inhibition of 2-hydroxyglutarate(2-HG) production by IDH1/2 mutant</li> <li>- 2-HG interferes with normal epigenetic mechanism of cells, leading to tumorigenesis</li> </ul>
<b>Indication - Primary</b>	<ul style="list-style-type: none"> <li>Acute Myeloid Leukemia (AML)</li> <li>Glioma</li> </ul>
<b>Indication - Expansion</b>	<ul style="list-style-type: none"> <li>Cholangiocarcinoma</li> </ul>
<b>Route of Administration</b>	<ul style="list-style-type: none"> <li>PO</li> </ul>
<b>Competitive Advantage</b>	<ul style="list-style-type: none"> <li>Drug discovery opportunity for <b>clinically well-validated</b> target</li> </ul>
<b>Data Files</b>	<ul style="list-style-type: none"> <li>In vitro : Enzyme &amp; Cellular assay (2-HG production inhibition)</li> <li>In vivo: PK/PD correlation experiments on-going</li> <li>Medicinal chemistry: lead generation, novel scaffold discovery</li> </ul>
<b>IP Status</b>	<ul style="list-style-type: none"> <li>Under preparation</li> </ul>
<b>Collaboration Model</b>	<ul style="list-style-type: none"> <li>Collaborative research followed by licensing out</li> </ul>
<b>Contact (Science)</b>	<ul style="list-style-type: none"> <li>Park Chi Hoon(, <a href="mailto:chpark@krict.re.kr">chpark@krict.re.kr</a>, +82-42-860-7161)</li> </ul>
<b>Contact (Licensing)</b>	<ul style="list-style-type: none"> <li>Moon Geun Jung (Technology marketing office, <a href="mailto:mgjung@krict.re.kr">mgjung@krict.re.kr</a>, +82-42-860-7746)</li> <li>Choon-gil Kim (Technology marketing office, <a href="mailto:joykim@krict.re.kr">joykim@krict.re.kr</a>, +82-42-860-7079)</li> <li>Kyung Sun Choi (Technology marketing office, <a href="mailto:chanian@krict.re.kr">chanian@krict.re.kr</a>, +82-42-860-7076)</li> </ul>